Selective Antibiotics Targeting tRNA Anticodon Stem Loop Fragments
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics face challenges in effectively treating Gram-negative bacteria, such as Pseudomonas aeruginosa and Klebsiella pneumoniae, due to evolving resistance mechanisms, leading to difficulties in treating infections like carbapenem-resistant Enterobacteriaceae, which are often deadly in hospitalized patients.
Innovation Solution
Development of methods to identify and utilize specific inhibitors targeting the tRNA anticodon stem loop fragments in bacteria, which inhibit protein synthesis by interfering with the binding of tRNA to ribosomes or aminoacyl synthetases, thereby preventing bacterial propagation without affecting beneficial bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Gram-negative bacteria, then initial treatment effectiveness is achieved, but bacterial resistance develops leading to treatment failure
Solution Approach 1:
The invention segments the tRNA molecule into specific fragments (anticodon stem loop, D-arm, acceptor stem) that serve as unique identifiers for different bacterial species. By targeting these specific fragments rather than entire tRNA molecules or general bacterial structures, the antibiotic achieves species-specific inhibition, preventing resistance development in beneficial bacteria while effectively treating pathogenic Gram-negative bacteria.
Solution Approach 2:
The invention applies local quality by designing antibiotics that bind to specific local regions of tRNA fragments unique to certain bacterial species. The anticodon stem loop region, for example, has species-specific sequence characteristics that allow selective targeting. This localized specificity ensures that only the intended pathogenic bacteria are affected, maintaining treatment reliability without promoting broad resistance.
2Adaptability or versatility
If broad-spectrum antibiotics are used to treat resistant bacteria, then coverage of multiple pathogens is achieved, but beneficial bacteria are affected causing side effects
Solution Approach 1:
The invention segments the bacterial population by targeting species-specific tRNA fragment sequences. Each antibiotic variant is designed to recognize and bind to unique sequence motifs in the tRNA fragments of specific Gram-negative bacterial species. This segmentation approach allows selective elimination of pathogenic bacteria while leaving beneficial bacteria with different tRNA sequences unaffected, thus avoiding side effects.
Solution Approach 2:
The invention employs local quality by focusing antibiotic binding activity on specific local sequence regions of tRNA fragments that differ between pathogenic and beneficial bacteria. The anticodon stem loop and other tRNA regions contain species-specific nucleotide sequences that serve as precise targeting sites, enabling the antibiotic to distinguish between harmful and beneficial bacterial populations.
3Ease of manufacture
If traditional antibiotic targets are used, then established treatment protocols are maintained, but resistance mechanisms render treatments ineffective
Solution Approach 1:
The invention extracts and isolates specific tRNA fragment sequences from the complex bacterial molecular machinery as unique therapeutic targets. By focusing on the extractable and identifiable tRNA fragment sequences (anticodon stem loop, D-arm, acceptor stem) that vary between bacterial species, the invention creates new antibiotic targets that are absent from traditional antibiotic mechanisms, thereby overcoming resistance while maintaining manufacturability through targeted molecular design.
Solution Approach 2:
The invention applies parameter changes by altering the molecular target parameters from traditional antibiotic targets (such as cell wall synthesis enzymes or protein synthesis ribosomes) to tRNA fragment sequences. This parameter change in target selection allows for the development of antibiotics with novel mechanisms of action that bypass existing resistance mechanisms, while the standardized molecular biology techniques for identifying and targeting these fragments maintain ease of manufacture and protocol standardization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach selectively inhibits the propagation of targeted bacteria, reducing the risk of side effects and the development of antibacterial resistance, providing a novel mechanism for treating infections caused by resistant pathogens.
Implementation Method 1
specific inhibitors of the propagation of these bacteria, and pharmaceutical compositions including the inhibitors and a pharmaceutically-acceptable carrier. Combination therapy using one or more of the inhibitors, and a second anti-bacterial compound, are also disclosed.
Data Source
AI summary
Methods are disclosed for identifying antibacterial compounds which inhibit propagation of selected spectrum bacteria, which bacteria use specific tRNA to code for Ala, Met, Ser, or Leu that other bacteria do not use. In one embodiment, the selected spectrum bacteria use GCA to code for Ala, whereas other bacteria use a different codon to code for alanine. The methods involve determining whether putative inhibitors promote or inhibit complex formation between the tRNA and a bacterial ribosome, or between the tRNA and an aminoacyl synthetase. Compounds which promote or inhibit complex formation can disrupt protein production, which bacteria need to propagate. The identified antibacterial compounds can selectively inhibit bacterial propagation. By limiting their effects to the selected spectrum bacteria, these compounds can treat or prevent specific bacterial infections without disrupting the normal bacterial flora, the patients' microbiome, or causing antibacterial resistance.